{"id":"mk19_niu","maxNiuRound":1,"roundDateLabels":{"1":"May 2022"},"nius":[{"id":"mk19_niu_1_cv_1","bookId":"cv","number":1,"niuRound":1,"affectedContent":[{"type":"table","id":"mk19_b_cv_t01"},{"type":"section","id":"mk19_b_cv_s2_2_1"},{"type":"section","id":"mk19_b_cv_s2_2_1_2"},{"type":"section","id":"mk19_b_cv_s2_2_2"},{"type":"section","id":"mk19_b_cv_s3_1_1"},{"type":"figure","id":"mk19_b_cv_f04"},{"type":"figure","id":"mk19_b_cv_f62"},{"type":"question","id":"mk19_b_cv_q002"},{"type":"question","id":"mk19_b_cv_q024"},{"type":"question","id":"mk19_b_cv_q057"},{"type":"question","id":"mk19_b_cv_q067"},{"type":"question","id":"mk19_b_cv_q088"},{"type":"question","id":"mk19_b_cv_q119"},{"type":"question","id":"mk19_b_cv_q120"},{"type":"question","id":"mk19_qq_q146"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"8ae6a7","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines published the 2021 Guideline on the Evaluation and Diagnosis of Chest Pain."]}," The guideline recommends stress testing with imaging over exercise electrocardiography for patients with stable chest pain and coronary CT as an alternative approach, particularly in patients aged 65 years or younger. It also recommends that chest pain not be described as atypical, but rather as cardiac, possibly cardiac, or noncardiac because these terms are more specific to the potential underlying diagnosis. The guideline includes a new model for estimating the pretest probabilities of obstructive coronary artery disease in symptomatic patients according to age, sex, and symptoms. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Oct 28:CIR0000000000001029. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34709879","target":"_blank"},"children":["PMID: 34709879"]}," doi: 10.1161/CIR.0000000000001029"]}]},{"id":"mk19_niu_1_cv_2","bookId":"cv","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_cv_s6_9_2"},{"type":"table","id":"mk19_b_cv_t26"},{"type":"question","id":"mk19_b_cv_q108"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"765aa4","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Heart Association published a 2021 scientific statement on Prevention of Viridans Group Streptococcal Infective Endocarditis."]}," The AHA no longer recommends clindamycin as an alternative to amoxicillin in penicillin-allergic patients who have an indication for endocarditis prophylaxis. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association. Circulation. 2021 May 18;143(20):e963-e978. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33853363","target":"_blank"},"children":["PMID: 33853363"]},". doi: 10.1161/CIR.0000000000000969"]}]},{"id":"mk19_niu_1_cv_3","bookId":"cv","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_cv_s4_4_2"},{"type":"boardbasics","id":"mk19_bb_cv_s5"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"6ef4d3","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["A randomized clinical trial of empagliflozin in heart failure with preserved ejection fraction was published in 2021."]}," The study found that empagliflozin reduced the combined risk for cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34449189","target":"_blank"},"children":["PMID: 34449189"]}," doi: 10.1056/NEJMoa2107038"]}]},{"id":"mk19_niu_1_cv_4","bookId":"cv","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_cv_s3_1_3_2"},{"type":"section","id":"mk19_b_cv_s3_1_3_3"},{"type":"section","id":"mk19_b_cv_s3_1_3_4"},{"type":"section","id":"mk19_b_cv_s3_2_2_2_1"},{"type":"section","id":"mk19_b_cv_s3_2_4_1"},{"type":"section","id":"mk19_b_cv_s3_3_4_3"},{"type":"question","id":"mk19_b_cv_q006"},{"type":"question","id":"mk19_b_cv_q029"},{"type":"question","id":"mk19_b_cv_q065"},{"type":"question","id":"mk19_qq_q111"},{"type":"question","id":"mk19_qq_q198"},{"type":"boardbasics","id":"mk19_bb_cv_s2"},{"type":"boardbasics","id":"mk19_bb_cv_s3"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"a306f5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines published the 2021 Guideline on Coronary Artery Revascularization."]}," The guideline recommends that in patients undergoing percutaneous coronary intervention (PCI), drug-eluting stents be used in preference to bare mental stents to prevent restenosis, myocardial infarction, or acute stent thrombosis. Other updates cover several topics, including PCI versus medical therapy, the optimal duration of dual antiplatelet therapy, and revascularization in patients with diabetes. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Dec 9:CIR0000000000001038. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34882435","target":"_blank"},"children":["PMID: 34882435"]}," doi: 10.1161/CIR.0000000000001038."]}]},{"id":"mk19_niu_1_cv_5","bookId":"cv","number":5,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_cv_s9_1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, Ault KA; Advisory Committee on Immunization Practices†. Recommended Adult Immunization Schedule, United States, 2022. Ann Intern Med. 2022. Epub ahead of print. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]},{"id":"mk19_niu_1_en_1","bookId":"en","number":1,"niuRound":1,"affectedContent":[{"type":"question","id":"mk19_b_en_q023"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"180646","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American College of Obstetricians and Gynecologists clinical practice guidelines on osteoporosis prevention, screening, and diagnosis"]},". The American College of Obstetricians and Gynecologists updated clinical practice guidelines to recommend therapeutic lifestyle changes to maintain bone health for all patients.",{"type":"tag","tagName":"strong","attrs":{},"children":[]}," ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["American College of Obstetricians and Gynecologists Committee on Clinical Practice Guidelines Gynecology. Osteoporosis prevention, screening, and diagnosis: ACOG clinical practice guideline no. 1. Obstet Gynecol. 2021;138:494-506. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34412075","target":"_blank"},"children":["PMID: 34412075"]}," doi:10.1097/AOG.0000000000004514"]}]},{"id":"mk19_niu_1_en_2","bookId":"en","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_1_1"},{"type":"section","id":"mk19_b_en_s1_1_3_3"},{"type":"section","id":"mk19_b_en_s1_1_3_4"},{"type":"table","id":"mk19_b_en_t01"},{"type":"table","id":"mk19_b_en_t02"},{"type":"table","id":"mk19_b_en_t04"},{"type":"question","id":"mk19_b_en_q081"},{"type":"question","id":"mk19_qq_q179"},{"type":"boardbasics","id":"mk19_bb_en_s1"},{"type":"boardbasics","id":"mk19_bb_en_s4"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"8fcbe6","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) screening recommendations."]}," The ADA updated diabetes classification criteria, screening recommendations, and diagnostic criteria, including recommendations on screening for prediabetes, antibody testing for persons with a relative with type 1 diabetes, and screening for gestational diabetes. Genetic counseling and testing are recommended for individuals with maturity-onset diabetes of the young. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S17-S38. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875","target":"_blank"},"children":["PMID: 34964875"]}," doi:10.2337/dc22-S002"]}]},{"id":"mk19_niu_1_en_3","bookId":"en","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_1_3_2_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"88e765","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) recommendations to prevent or delay type 2 diabetes onset."]}," The ADA recommends an intensive lifestyle behavior change program to delay or prevent development of type 2 diabetes in persons at high risk. The ADA also recommends considering metformin to prevent type 2 diabetes in persons with prediabetes and women with a history of gestational diabetes. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["American Diabetes Association Professional Practice Committee. 3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S39-S45. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964876","target":"_blank"},"children":["PMID: 34964876"]}," doi:10.2337/dc22-S003"]}]},{"id":"mk19_niu_1_en_4","bookId":"en","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_1_4_1"},{"type":"section","id":"mk19_b_en_s1_1_4_4"},{"type":"section","id":"mk19_b_en_s1_6"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"7206e2","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) recommendations to improve health outcomes."]}," The ADA updated recommendations on behavioral changes to improve health outcomes in persons with diabetes, including use of digital coaching and self-management, dietary recommendations, and monitoring of cognitive capacity. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S60-S82. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964866","target":"_blank"},"children":["PMID: 34964866"]}," doi:10.2337/dc22-S005"]}]},{"id":"mk19_niu_1_en_5","bookId":"en","number":5,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_1_4_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"2c3459","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) recommendations on technology use."]}," The ADA updated standards on use of technology, including additional considerations for insulin measurement regimens and recommendations for use of real-time or intermittently scanned continuous glucose monitoring. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S97-S112. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964871","target":"_blank"},"children":["PMID: 34964871"]}," doi:10.2337/dc22-S007"]}]},{"id":"mk19_niu_1_en_6","bookId":"en","number":6,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_1_4_5_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"fb814d","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) recommendations on pharmacologic treatment of type 2 diabetes."]}," If insulin is used, the ADA recommends combination therapy with a glucagon-like peptide 1 receptor agonist for greater efficacy and durability of treatment effect. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S125-S143. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964831","target":"_blank"},"children":["PMID: 34964831"]}," doi:10.2337/dc22-S009"]}]},{"id":"mk19_niu_1_en_7","bookId":"en","number":7,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_1_4_5_2"},{"type":"section","id":"mk19_b_en_s1_5_1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"e21a94","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) recommendations to reduce cardiovascular risks."]}," The ADA updated standards to recommend a sodium-glucose cotransporter 2 inhibitor, a glucagon-like peptide 1 receptor agonist, or combination therapy of the two for patients with type 2 diabetes and other risk factors to reduce the risk for worsening heart failure, adverse cardiovascular events, or adverse kidney events. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S144-S174. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964815","target":"_blank"},"children":["PMID: 34964815"]}," doi:10.2337/dc22-S010"]}]},{"id":"mk19_niu_1_en_8","bookId":"en","number":8,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_5_3"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"8f8683","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) recommendations for treatment of diabetic nephropathy."]}," The ADA strongly recommends an ACE inhibitor or angiotensin receptor blocker as first-line therapy to slow progression of nephropathy and prevent cardiovascular disease in specific patients. Other recommendations include therapy to reduce chronic kidney disease progression and cardiovascular events as well as alternative treatment options for certain patients who are at increased risk for cardiovascular events or chronic kidney disease progression. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S175-S184. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964873","target":"_blank"},"children":["PMID: 34964873"]}," doi:10.2337/dc22-S011"]}]},{"id":"mk19_niu_1_en_9","bookId":"en","number":9,"niuRound":1,"affectedContent":[{"type":"question","id":"mk19_b_en_q067"},{"type":"question","id":"mk19_qq_q216"},{"type":"boardbasics","id":"mk19_bb_en_s1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"e9f1a2","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Diabetes Association (ADA) recommendations for diabetic neuropathy treatment."]}," The ADA updated recommended treatments for painful diabetic peripheral neuropathy, including initial therapies for neuropathic pain. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S185-S194. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964887","target":"_blank"},"children":["PMID: 34964887"]}," doi:10.2337/dc22-S012"]}]},{"id":"mk19_niu_1_en_10","bookId":"en","number":10,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_en_s1_5_4"},{"type":"question","id":"mk19_qq_q216"},{"type":"boardbasics","id":"mk19_bb_en_s1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"e05ab3","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated American Academy of Neurology (AAN) guideline on treatment of painful diabetic polyneuropathy."]}," The AAN Guideline Subcommittee updated practice guidelines on topical and oral treatments for painful diabetic polyneuropathy. The AAN recommends use of tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and/or sodium channel blockers, although only certain agents are approved by the FDA to treat diabetic neuropathy; opioids, tramadol, or tapentadol are not recommended. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}," "]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee. Neurology. 2022;98:31-43. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34965987","target":"_blank"},"children":["PMID: 34965987"]}," doi:10.1212/WNL.0000000000013038"]}]},{"id":"mk19_niu_1_en_11","bookId":"en","number":11,"niuRound":1,"affectedContent":[{"type":"question","id":"mk19_b_en_q080"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175:432-443. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]},{"id":"mk19_niu_1_gi_1","bookId":"gi","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s1_2_1_1"},{"type":"section","id":"mk19_a_gi_s1_2_1_2_3"},{"type":"section","id":"mk19_a_gi_s1_2_1_2_4"},{"type":"section","id":"mk19_a_gi_s1_2_1_3"},{"type":"section","id":"mk19_a_gi_s2_4_3"},{"type":"question","id":"mk19_a_gi_q076"},{"type":"question","id":"mk19_a_gi_q081"},{"type":"boardbasics","id":"mk19_bb_gi_s3"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"e76ae6","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American College of Gastroenterology provides updated guidelines for the diagnosis and management of gastroesophageal reflux disease (GERD)."]}," This new document provides updated, evidence-based recommendations and practical guidance for the evaluation and management of GERD, including pharmacologic, lifestyle, surgical, and endoscopic management. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117:27-56. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34807007","target":"_blank"},"children":["PMID: 34807007"]}," doi:10.14309/ajg.0000000000001538"]}]},{"id":"mk19_niu_1_gi_2","bookId":"gi","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s4_4_5_1_4"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"48519c","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The FDA issued a drug safety communication on Janus kinase inhibitors."]}," The communication indicates that tofacitinib increases the risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. September 16, 2021. Accessed October 6, 2021. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"]}]},{"id":"mk19_niu_1_gi_3","bookId":"gi","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s4_4_5_2_4"},{"type":"section","id":"mk19_a_gi_s4_4_5_2_5"},{"type":"question","id":"mk19_a_gi_q066"},{"type":"question","id":"mk19_qq_q030"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"6d924d","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Gastroenterological Association Institute Clinical Guidelines Committee provides updated guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn disease in adults."]}," Evidence supports use of multiple drug classes, including tumor necrosis factor-α (TNF-α) antagonists, anti-integrins, anti-interleukin 12/23 inhibitors, methotrexate (subcutaneous/intramuscular), and glucocorticoids for induction of remission, and the use TNF-α antagonists, anti-integrins, anti-interleukin 12/23 inhibitors, thiopurines, and methotrexate (subcutaneous/intramuscular) for the maintenance of remission. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160:2496-2508. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34051983","target":"_blank"},"children":["PMID: 34051983"]}," doi:10.1053/j.gastro.2021.04.022"]}]},{"id":"mk19_niu_1_gi_4","bookId":"gi","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s4_4_6"},{"type":"question","id":"mk19_a_gi_q028"},{"type":"boardbasics","id":"mk19_bb_gi_s17"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"5cb4a0","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Gastroenterological Association provides an update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases"]},". The new guidelines favor “smart” approaches that emphasize careful inspection and targeted sampling of visible and subtle lesions using newer technologies, as well as endoscopic management of most lesions. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology. 2021;161:1043-1051.e4. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34416977","target":"_blank"},"children":["PMID: 34416977"]}," doi:10.1053/j.gastro.2021.05.063"]}]},{"id":"mk19_niu_1_gi_5","bookId":"gi","number":5,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s4_5_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"b21e12","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Evidence-based recommendations on the use of over-the-counter therapies for chronic constipation."]}," The study found good evidence to recommend polyethylene glycol or senna as first-line laxatives and moderate evidence supporting fiber supplements, fruits, stimulant laxatives, and magnesium-based products",{"type":"tag","tagName":"strong","attrs":{},"children":["."]}," ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol. 2021;116:1156-1181. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33767108","target":"_blank"},"children":["PMID: 33767108"]}," doi:10.14309/ajg.0000000000001222"]}]},{"id":"mk19_niu_1_gi_6","bookId":"gi","number":6,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s4_8"},{"type":"question","id":"mk19_a_gi_q006"},{"type":"boardbasics","id":"mk19_bb_gi_s20"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"d7bfee","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Clinical Guidelines Committee of the American College of Physicians published clinical guidelines on the diagnosis and management of acute left-sided colonic diverticulitis."]}," The committee provides three clinical recommendations, including the use of CT imaging when necessary, managing in an outpatient setting, and judicious use of antibiotics. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Qaseem A, Etxeandia-Ikobaltzeta I, Lin JS, et al; Clinical Guidelines Committee of the American College of Physicians. Diagnosis and management of acute left-sided colonic diverticulitis: a clinical guideline from the American College of Physicians. Ann Intern Med. 2022;175:399-415. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35038273","target":"_blank"},"children":["PMID: 35038273"]}," doi:10.7326/M21-2710"]}]},{"id":"mk19_niu_1_gi_7","bookId":"gi","number":7,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s4_10_1_1"},{"type":"section","id":"mk19_a_gi_s4_10_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"9842d0","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["American College of Gastroenterology provides clinical guidelines on the management of benign anorectal disorders"]},". These guidelines summarize the preferred approach to the evaluation and management of defecation disorders, proctalgia syndromes, hemorrhoids, anal fissures, and fecal incontinence in adults. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Wald A, Bharucha AE, Limketkai B, et al. ACG clinical guidelines: management of benign anorectal disorders. Am J Gastroenterol. 2021;116:1987-2008. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34618700","target":"_blank"},"children":["PMID: 34618700"]}," doi:10.14309/ajg.0000000000001507"]}]},{"id":"mk19_niu_1_gi_8","bookId":"gi","number":8,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s6_7_1"},{"type":"question","id":"mk19_a_gi_q035"},{"type":"boardbasics","id":"mk19_bb_gi_s28"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"f96691","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease"]},". A rationale is provided supporting proposed steps to assist clinicians in diagnosing and managing nonalcoholic fatty liver disease with clinically significant fibrosis. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657-1669. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34602251","target":"_blank"},"children":["PMID: 34602251"]}," doi:10.1053/j.gastro.2021.07.049"]}]},{"id":"mk19_niu_1_gi_9","bookId":"gi","number":9,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s6_10_4"},{"type":"section","id":"mk19_a_gi_s6_10_5"},{"type":"section","id":"mk19_a_gi_s6_10_7"},{"type":"question","id":"mk19_a_gi_q003"},{"type":"question","id":"mk19_a_gi_q039"},{"type":"question","id":"mk19_a_gi_q054"},{"type":"boardbasics","id":"mk19_bb_gi_s31"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"60856d","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["American Association for the Study of Liver Diseases (AASLD) guidance on diagnosis, evaluation, and management of ascites and hepatorenal syndrome in patients with chronic liver disease."]}," The update encompasses data from the past decade, and it replaces the prior AASLD guideline on the same topic that was published in 2012 . ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1014-1048. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33942342","target":"_blank"},"children":["PMID: 33942342"]}," doi:10.1002/hep.31884"]}]},{"id":"mk19_niu_1_gi_10","bookId":"gi","number":10,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s8_2_2"},{"type":"section","id":"mk19_a_gi_s8_2_3_1"},{"type":"section","id":"mk19_a_gi_s8_2_3_3"},{"type":"question","id":"mk19_a_gi_q052"},{"type":"question","id":"mk19_a_gi_q068"},{"type":"question","id":"mk19_a_gi_q088"},{"type":"boardbasics","id":"mk19_bb_gi_s35"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"eb72a7","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American College of Gastroenterology updated clinical guidelines for upper gastrointestinal and ulcer bleeding."]}," Recommendations include a restrictive hemoglobin threshold for erythrocyte transfusion in patients with upper gastrointestinal bleeding, and endoscopy is suggested within 24 hours after presentation. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116:899-917. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33929377","target":"_blank"},"children":["PMID: 33929377"]}," doi:10.14309/ajg.0000000000001245"]}]},{"id":"mk19_niu_1_gi_11","bookId":"gi","number":11,"niuRound":1,"affectedContent":[{"type":"question","id":"mk19_a_gi_q055"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"bd3d7c","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American College of Gastroenterology Practice Parameters Committee clinical guidelines for diagnosis and management of idiosyncratic drug-induced liver injury."]}," The guideline provides information regarding the diagnosis and management of idiosyncratic drug-induced liver injury. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Chalasani NP, Maddur H, Russo MW, et al; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116:878-898. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33929376","target":"_blank"},"children":["PMID: 33929376"]}," doi:10.14309/ajg.0000000000001259"]}]},{"id":"mk19_niu_1_gi_12","bookId":"gi","number":12,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gi_s4_4_6"},{"type":"boardbasics","id":"mk19_bb_gi_s17"},{"type":"boardbasics","id":"mk19_bb_gi_s23"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:229-233. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35176010","target":"_blank"},"children":["PMID: 35176010"]}," doi: 10.15585/mmwr.mm7107a1"]}]},{"id":"mk19_niu_1_gm_1","bookId":"gm","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gm_s5_3_2_1"},{"type":"section","id":"mk19_a_gm_s7_2_2_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"557d30","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["A ",{"type":"tag","tagName":"i","attrs":{},"children":["BMJ"]}," Rapid Recommendation was published in 2021 on medical cannabis or cannabinoids for chronic pain."]}," The expert panel issued a weak recommendation to offer a trial of noninhaled medical cannabis or cannabinoids, in addition to standard care and management (if not sufficient), for people living with chronic cancer or noncancer pain. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021;374:n2040. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34497062","target":"_blank"},"children":["PMID: 34497062"]}," doi: 10.1136/bmj.n2040"]}]},{"id":"mk19_niu_1_gm_2","bookId":"gm","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gm_s6_3_1"},{"type":"boardbasics","id":"mk19_bb_gm_s10"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"97c7bc","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Society of Clinical Oncology published a 2021 guideline on the management of dyspnea in advanced cancer."]}," The guideline includes recommendations on screening and assessment, treatment of underlying causes, referral to palliative care, and pharmacologic and nonpharmacologic interventions. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Hui D, Bohlke K, Bao T, Campbell TC, Coyne PJ, Currow DC, Gupta A, Leiser AL, Mori M, Nava S, Reinke LF, Roeland EJ, Seigel C, Walsh D, Campbell ML. Management of dyspnea in advanced cancer: ASCO guideline. J Clin Oncol. 2021 Apr 20;39(12):1389-1411. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33617290","target":"_blank"},"children":["PMID: 33617290"]}," doi: 10.1200/JCO.20.03465"]}]},{"id":"mk19_niu_1_gm_3","bookId":"gm","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gm_s8_2_3"},{"type":"question","id":"mk19_a_gm_q046"},{"type":"question","id":"mk19_a_gm_q060"},{"type":"question","id":"mk19_a_gm_q072"},{"type":"question","id":"mk19_a_gm_q086"},{"type":"boardbasics","id":"mk19_bb_gm_s12"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"2af3e7","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American College of Cardiology (ACC) published the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia."]}," The ACC decision pathway includes evaluation and management of secondary causes, implementation of diet and lifestyle changes, and optimization of glycemic control. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Virani SS, Morris PB, Birtcher KK, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Jul 28, 2021. doi: 10.1016/j.jacc.2021.06.011"]}]},{"id":"mk19_niu_1_gm_4","bookId":"gm","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gm_s6_3_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"ef805c","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["A clinical trial published in 2021 examined the effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life."]}," The study found that prophylactic subcutaneous scopolamine butylbromide reduces the occurrence of \"death rattle\" compared with placebo without clear evidence of an increase in adverse effects, but it may prolong the dying phase by a few hours. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["van Esch HJ, van Zuylen L, Geijteman ECT, et al. Effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life: the SILENCE randomized clinical trial. JAMA. 2021;326:1268-1276. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34609452","target":"_blank"},"children":["PMID: 34609452"]}," doi: 10.1001/jama.2021.14785"]}]},{"id":"mk19_niu_1_gm_5","bookId":"gm","number":5,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_gm_s8_2_2"},{"type":"table","id":"mk19_a_gm_t41"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"600e27","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The U.S. Food and Drug Administration recently approved two new drugs for lowering low-density lipoprotein cholesterol."]}," Bempedoic acid and inclisiran are now FDA-approved for use as adjuncts to maximally tolerated statin therapy. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Bempedoic acid (Nexletol) for lowering LDL-cholesterol. Med Lett Drugs Ther. 2020 Apr 6;62(1595):53-55. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/32324179","target":"_blank"},"children":["PMID: 32324179"]}]},{"type":"tag","tagName":"span","attrs":{},"children":["Inclisiran (Leqvio) for LDL-cholesterol lowering. Med Lett Drugs Ther. 2022;64:43-45. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35294427","target":"_blank"},"children":["PMID: 35294427"]}]}]},{"id":"mk19_niu_1_gm2_1","bookId":"gm2","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s1_1_2"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"c90f80","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The U.S. Preventive Services Task Force (USPSTF) issued new recommendations for screening for atrial fibrillation in adults."]}," The USPSTF concluded that there is insufficient evidence to assess the benefits or harms of screening for atrial fibrillation with ECG or other recording modalities. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")."]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force. Screening for atrial fibrillation: US Preventive Services Task Force recommendation statement. JAMA. 2022;327:360-367. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35076659","target":"_blank"},"children":["PMID: 35076659"]}," doi:10.1001/jama.2021.23732"]}]},{"id":"mk19_niu_1_gm2_2","bookId":"gm2","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s1_2_3_1_5"},{"type":"question","id":"mk19_b_gm_q117"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"51ea67","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Diabetes Association (ADA) issued new recommendations for screening for diabetes in adults."]}," According to the ADA's Standards of Medical Care in Diabetes, screening for diabetes should begin at age 35 years for all adults, regardless of risk factors. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S17-S38. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875","target":"_blank"},"children":["PMID: 34964875"]}," doi:10.2337/dc22-S002"]}]},{"id":"mk19_niu_1_gm2_3","bookId":"gm2","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s1_2_3_1_10"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"8ccec6","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American College of Obstetricians and Gynecologists (ACOG) have issued new practice guidelines for the prevention, screening, and diagnosis of osteoporosis."]}," The new ACOG clinical practice guideline includes updated recommendations for osteoporosis, including prevention, screening and diagnosis, and rescreening intervals. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["American College of Obstetricians and Gynecologists Committee on Clinical Practice Guidelines. Osteoporosis prevention, screening, and diagnosis: ACOG clinical practice guideline no. 1. Obstet Gynecol. 2021;138:494-506. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34412075","target":"_blank"},"children":["PMID: 34412075"]}," doi:10.1097/AOG.0000000000004514"]}]},{"id":"mk19_niu_1_gm2_4","bookId":"gm2","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s1_2_3_5_3"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"efd49a","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The U.S. Multi-Society Task Force (MSTF) has issued an update of recommendations for colorectal cancer (CRC) screening."]}," The MSTF recommendations are a focused update to their 2017 CRC screening recommendations and specifically addresses the age to start and stop screening. According to the MSTF, sufficient data support the recommendation of CRC screening in average-risk persons beginning at age 45. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on colorectal cancer. Gastroenterology. 2022;162:285-299. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34794816","target":"_blank"},"children":["PMID: 34794816"]}," doi:10.1053/j.gastro.2021.10.007"]}]},{"id":"mk19_niu_1_gm2_5","bookId":"gm2","number":5,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s1_3_1_1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"692844","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention issued new recommendations for prevention and control of seasonal influenza with vaccines."]}," This report updates the ACIP 2020-21 influenza vaccination recommendations. There are several primary items addressed in these updates, including that all seasonal influenza vaccines available in the United States for the 2021-22 season are expected to be quadrivalent as well as guidance on timing of influenza vaccination for pregnant women. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 influenza season. MMWR Recomm Rep. 2021;70:1-28. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34448800","target":"_blank"},"children":["PMID: 34448800"]}," doi:10.15585/mmwr.rr7005a1"]}]},{"id":"mk19_niu_1_gm2_6","bookId":"gm2","number":6,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s1_3_2_1"},{"type":"section","id":"mk19_b_gm_s1_3_2_2"},{"type":"section","id":"mk19_b_gm_s1_3_2_7"},{"type":"table","id":"mk19_b_gm_t11"},{"type":"table","id":"mk19_b_gm_t13"},{"type":"question","id":"mk19_b_gm_q006"},{"type":"question","id":"mk19_b_gm_q020"},{"type":"question","id":"mk19_b_gm_q033"},{"type":"question","id":"mk19_b_gm_q070"},{"type":"question","id":"mk19_b_gm_q121"},{"type":"boardbasics","id":"mk19_bb_gm_s31"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"a78ac7","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 adult immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175:432-443. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]},{"id":"mk19_niu_1_gm2_7","bookId":"gm2","number":7,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s4_1_2"},{"type":"section","id":"mk19_b_gm_s4_5_1"},{"type":"table","id":"mk19_b_gm_t22"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"4e5458","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Society for Perioperative Assessment and Quality Improvement (SPAQI) has issued a consensus statement for preoperative management of endocrine and urologic drugs in adults."]}," Utilizing its multidisciplinary membership, SPAQI aims to improve perioperative care. This consensus statement provides guidance on preoperative management in endocrine, hormonal, and urologic medications, using a modified Delphi approach to critically review literature and develop consensus recommendations.",{"type":"tag","tagName":"strong","attrs":{},"children":[]}," (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Pfeifer KJ, Selzer A, Mendez CE, et al. Preoperative management of endocrine, hormonal, and urologic medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement. Mayo Clin Proc. 2021;96:1655-1669. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33714600","target":"_blank"},"children":["PMID: 33714600"]}," doi:10.1016/j.mayocp.2020.10.002"]}]},{"id":"mk19_niu_1_gm2_8","bookId":"gm2","number":8,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s6_4"},{"type":"question","id":"mk19_qq_q214"},{"type":"boardbasics","id":"mk19_bb_gm_s38"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"5565c4","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Urological Association (AUA) issued new guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH)."]}," Nineteen guideline statements regarding the evaluation, work-up, and medical management of LUTS attributed to BPH were developed by the AUA to guide primary care and urologic health care providers. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. J Urol. 2021;206:806-817. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34384237","target":"_blank"},"children":["PMID: 34384237"]}," doi:10.1097/JU.0000000000002183"]}]},{"id":"mk19_niu_1_gm2_9","bookId":"gm2","number":9,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_gm_s7_7_2"},{"type":"table","id":"mk19_b_gm_t54"},{"type":"table","id":"mk19_b_gm_t80"},{"type":"question","id":"mk19_b_gm_q025"},{"type":"question","id":"mk19_b_gm_q085"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"7f92f8","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Centers for Disease Control and Prevention issued new guidelines for the treatment of sexually transmitted infections (STIs)."]}," As an update to the 2015 guidelines, the 2021 guidelines for treatment of STIs address many topics, including updated treatment recommendations for ",{"type":"tag","tagName":"i","attrs":{},"children":["Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, "]},"and ectoparasites; addition of metronidazole to the treatment regimen for pelvic inflammatory disease; and alternative treatment options for bacterial vaginosis. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1-187. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34292926","target":"_blank"},"children":["PMID: 34292926"]}," doi:10.15585/mmwr.rr7004a1"]}]},{"id":"mk19_niu_1_hm_1","bookId":"hm","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_hm_s9_2_3_4"},{"type":"section","id":"mk19_b_hm_s9_3_3"},{"type":"section","id":"mk19_b_hm_s9_4_1"},{"type":"table","id":"mk19_b_hm_t35"},{"type":"question","id":"mk19_b_hm_q054"},{"type":"question","id":"mk19_qq_q159"},{"type":"boardbasics","id":"mk19_bb_hm_s26"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"3c0aaf","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Antithrombotic therapy for venous thromboembolism."]}," The American College of Chest Physicians updated CHEST guidelines on therapy in venous thromboembolism (VTE), including antithrombotic management of VTE, secondary prevention, and risk reduction of postthrombotic syndrome. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160:e545-e608. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34352278","target":"_blank"},"children":["PMID: 34352278"]}," doi: 10.1016/j.chest.2021.07.055"]}]},{"id":"mk19_niu_1_hm_2","bookId":"hm","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_hm_s3_4_3"},{"type":"question","id":"mk19_b_hm_q004"},{"type":"question","id":"mk19_b_hm_q042"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:229-233. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35176010","target":"_blank"},"children":["PMID: 35176010"]}," doi: 10.15585/mmwr.mm7107a1"]}]},{"id":"mk19_niu_1_id_1","bookId":"id","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_id_s15_8"},{"type":"table","id":"mk19_a_id_t48"},{"type":"table","id":"mk19_a_id_t49"},{"type":"question","id":"mk19_a_id_q010"},{"type":"question","id":"mk19_a_id_q061"},{"type":"question","id":"mk19_a_id_q095"},{"type":"question","id":"mk19_qq_q051"},{"type":"question","id":"mk19_qq_q084"},{"type":"boardbasics","id":"mk19_bb_id_s31"},{"type":"boardbasics","id":"mk19_bb_id_s37"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"aa6a78","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Infectious Diseases Society of America and Society for Healthcare Epidemiology of America published a focused update on management of ",{"type":"tag","tagName":"i","attrs":{},"children":["Clostridioides difficile"]}," infection."]}," Updates include listing oral fidaxomicin (preferred) or oral vancomycin (alternative) as first-line agents for nonsevere or severe initial or recurrent infection, oral metronidazole for initial infection only if first-line agents are unavailable, and adjunctive bezlotoxumab in specific circumstances. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73:755-757. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34492699","target":"_blank"},"children":["PMID: 34492699"]}," doi: 10.1093/cid/ciab718"]}]},{"id":"mk19_niu_1_id_2","bookId":"id","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_id_s14_6"},{"type":"section","id":"mk19_a_id_s18_4_2"},{"type":"table","id":"mk19_a_id_t35"},{"type":"table","id":"mk19_a_id_t39"},{"type":"table","id":"mk19_a_id_t52"},{"type":"question","id":"mk19_a_id_q014"},{"type":"question","id":"mk19_a_id_q024"},{"type":"question","id":"mk19_a_id_q071"},{"type":"question","id":"mk19_qq_q109"},{"type":"boardbasics","id":"mk19_bb_id_s38"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:229-233. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35176010","target":"_blank"},"children":["PMID: 35176010"]}," doi: 10.15585/mmwr.mm7107a1"]}]},{"id":"mk19_niu_1_id_3","bookId":"id","number":3,"niuRound":1,"affectedContent":[{"type":"table","id":"mk19_a_id_t30"},{"type":"table","id":"mk19_a_id_t31"},{"type":"table","id":"mk19_a_id_t33"},{"type":"question","id":"mk19_a_id_q092"},{"type":"question","id":"mk19_qq_q045"},{"type":"boardbasics","id":"mk19_bb_gm_s69"},{"type":"boardbasics","id":"mk19_bb_id_s20"},{"type":"boardbasics","id":"mk19_bb_id_s21"},{"type":"boardbasics","id":"mk19_bb_id_s22"},{"type":"boardbasics","id":"mk19_bb_id_s23"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"743cb1","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The CDC updated treatment guidelines for sexually transmitted infections."]}," Updated recommendations include those for treatment of ",{"type":"tag","tagName":"i","attrs":{},"children":["Neisseria gonorrhoeae"]}," and ",{"type":"tag","tagName":"i","attrs":{},"children":["Chlamydia trachomatis"]},", the addition of metronidazole to regimens for pelvic inflammatory disease, and revisions to some preferred and alternate regimens. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1-187. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34292926","target":"_blank"},"children":["PMID: 34292926"]}," doi:10.15585/mmwr.rr7004a1"]}]},{"id":"mk19_niu_1_id_4","bookId":"id","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_id_s13_4"},{"type":"table","id":"mk19_a_id_t38"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"002fe0","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The CDC provided recommendations regarding treatment and pre- and postexposure prophylaxis of plague."]}," Recommendations for treatment have revised preferred and alternative agents, as well as expanded prophylaxis regimens. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR Recomm Rep. 2021;70:1-27. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34264565","target":"_blank"},"children":["PMID: 34264565"]}," doi: 10.15585/mmwr.rr7003a1"]}]},{"id":"mk19_niu_1_np_1","bookId":"np","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_np_s4_11_1_4"},{"type":"section","id":"mk19_a_np_s6_3_1_4"},{"type":"section","id":"mk19_a_np_s12_6_1_1"},{"type":"boardbasics","id":"mk19_bb_np_s13"},{"type":"boardbasics","id":"mk19_bb_np_s22"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"7ea576","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Kidney Disease: Improving Global Outcomes (KDIGO) issued a synopsis of a new clinical practice guideline for the management of blood pressure (BP) in patients with chronic kidney disease (CKD) who are not receiving dialysis."]}," This 2021 KDIGO clinical practice guideline is an update of the 2012 guideline addressing the same topic. Based on new evidence, the guideline provides 11 recommendations regarding the diagnosis and management of high BP in adults with CKD, with the exception of patients undergoing kidney replacement therapy. Included are recommendations for standardized BP measurement and a systolic BP target of less than 120 mm Hg. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Tomson CRV, Cheung AK, Mann JFE, et al. Management of blood pressure in patients with chronic kidney disease not receiving dialysis: synopsis of the 2021 KDIGO clinical practice guideline. Ann Intern Med. 2021;174:1270-1281. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34152826","target":"_blank"},"children":["PMID: 34152826"]}," doi:10.7326/M21-0834"]}]},{"id":"mk19_niu_1_np_2","bookId":"np","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_np_s6_3_2_4"},{"type":"section","id":"mk19_a_np_s6_3_4_4"},{"type":"section","id":"mk19_a_np_s6_4_2_4"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"314069","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Kidney Disease: Improving Global Outcomes (KDIGO) issued an executive summary of the 2021 guideline for management of glomerular diseases."]}," As an update to the KDIGO 2021 guideline on the same topic, this guideline addresses the diagnosis and management of persons with glomerular diseases, including nephrotic syndrome, minimal change disease, focal segmental glomerulosclerosis, anti-glomerular basement membrane antibody disease, among others. Furthermore, the guideline addresses the subtype of complement-mediated diseases and proposes research recommendations for areas in which knowledge gaps exist. (",{"type":"tag","tagName":"i","attrs":{},"children":["Updated May 2022"]},")"]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100:753-779. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34556300","target":"_blank"},"children":["PMID: 34556300"]}," doi:10.1016/j.kint.2021.05.015"]}]},{"id":"mk19_niu_1_np_3","bookId":"np","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_np_s12_8_2"},{"type":"question","id":"mk19_a_np_q042"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"a78ac7","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 adult immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175:432-443. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]},{"id":"mk19_niu_1_nr_1","bookId":"nr","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_nr_s5_5_1_4"},{"type":"question","id":"mk19_a_nr_q016"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"1a4011","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Diagnostic criteria for traumatic encephalopathy syndrome (TES)."]}," The National Institute of Neurological Disorders and Stroke developed diagnostic criteria for TES. A diagnosis of TES requires repetitive head impacts; core clinical features of cognitive impairment or dysregulation; a progressive course; and that the symptoms are not fully accounted for by any other conditions. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Katz DI, Bernick C, Dodick DW, et al. National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for traumatic encephalopathy syndrome. Neurology. 2021;96:848-863. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33722990","target":"_blank"},"children":["PMID: 33722990"]}," doi:10.1212/WNL.0000000000011850"]}]},{"id":"mk19_niu_1_nr_2","bookId":"nr","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_nr_s6_2_1_4"},{"type":"table","id":"mk19_a_nr_t34"},{"type":"boardbasics","id":"mk19_bb_nr_s10"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"a0ec92","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["American Academy of Neurology (AAN) guidelines on treatment of early-stage Parkinson disease."]}," The AAN Guideline Subcommittee issued recommendations on initiating dopaminergic treatment of motor symptoms for patients with early-stage Parkinson disease, including preference for levodopa as initial therapy, preference for immediate-release formulations of levodopa, and use of dopamine agonists to treat motor symptoms in younger patients who are at higher risk for dyskinesia. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Pringsheim T, Day GS, Smith DB, et al; Guideline Subcommittee of the AAN. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN Guideline Subcommittee. Neurology. 2021;97:942-957. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34782410","target":"_blank"},"children":["PMID: 34782410"]}," doi:10.1212/WNL.0000000000012868"]}]},{"id":"mk19_niu_1_nr_3","bookId":"nr","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_nr_s10_4_1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"c39bdc","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated practice parameter on use of antiepileptic drugs (AEDs) in treatment of brain tumors."]}," The Society for Neuro-Oncology and the European Association of Neuro-Oncology updated practice parameters on the use of AEDs in patients with brain tumors. Of note, the practice parameters state that evidence is insufficient to support the use of AEDs to reduce the risk of peri- or postoperative seizures in patients undergoing surgery.",{"type":"tag","tagName":"strong","attrs":{},"children":[]}," ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23:1835-1844. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34174071","target":"_blank"},"children":["PMID: 34174071"]}," doi:10.1093/neuonc/noab152"]}]},{"id":"mk19_niu_1_nr_4","bookId":"nr","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_nr_s3_4_1_2"},{"type":"boardbasics","id":"mk19_bb_nr_s4"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"72795e","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Updated antiepileptic drug (AED) withdrawal guidance."]}," The American Academy of Neurology Guidelines Subcommittee updated practice parameters pertaining to the withdrawal of antiseizure medication in seizure-free patients. The American Academy of Neurology recommends discussing the benefits and risks of withdrawing AEDs in adults who have been seizure-free for at least 2 years. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Gloss D, Pargeon K, Pack A, et al; AAN Guideline Subcommittee. Antiseizure medication withdrawal in seizure-free patients: practice advisory update summary: report of the AAN Guideline Subcommittee. Neurology. 2021;97:1072-1081. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34873018","target":"_blank"},"children":["PMID: 34873018"]}," doi:10.1212/WNL.0000000000012944"]}]},{"id":"mk19_niu_1_nr_5","bookId":"nr","number":5,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_nr_s10_2"},{"type":"boardbasics","id":"mk19_bb_nr_s20"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"d458a1","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Guidance on treatment for brain metastases."]}," The American Society of Clinical Oncology, the Society for Neuro-Oncology, and the American Society for Radiation Oncology released guidance on treatment for patients with brain metastases from solid tumors. Local therapy should be considered for patients with symptomatic brain metastases; patients with large tumors and mass effect may benefit from resection. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}," "]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022;40:492-516. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34932393","target":"_blank"},"children":["PMID: 34932393"]}," doi:10.1200/JCO.21.02314"]}]},{"id":"mk19_niu_1_nr_6","bookId":"nr","number":6,"niuRound":1,"affectedContent":[{"type":"question","id":"mk19_a_nr_q087"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175:432-443. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]},{"id":"mk19_niu_1_on_1","bookId":"on","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_on_s2_6"},{"type":"section","id":"mk19_a_on_s2_7"},{"type":"boardbasics","id":"mk19_bb_on_s1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"d02970","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Society of Clinical Oncology issued a guideline on neoadjuvant therapy for breast cancer."]}," The guideline provides recommendations on which patients with breast cancer are candidates for neoadjuvant therapy, how response should be measured in patients receiving neoadjuvant therapy, and which neoadjuvant treatments are most appropriate for patients with triple-negative breast cancer or hormone receptor–positive/",{"type":"tag","tagName":"i","attrs":{},"children":["HER2"]},"-negative breast cancer. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485-1505. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33507815","target":"_blank"},"children":["PMID: 33507815"]}," doi: 10.1200/JCO.20.03399."]}]},{"id":"mk19_niu_1_on_2","bookId":"on","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_on_s5_1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"e35276","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The U.S. Preventive Services Task Force (USPSTF) updated its 2016 recommendations for colorectal cancer screening."]}," These recommendations address the benefits and harms of screening for colorectal cancer in adults aged 40 years and older and how these findings vary by age, sex, or race/ethnicity. Of note, the USPSTF conditionally recommends routine colorectal cancer screening to begin at age 45 years. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2021;325:1965-1977. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34003218","target":"_blank"},"children":["PMID: 34003218"]}," doi: 10.1001/jama.2021.6238."]}]},{"id":"mk19_niu_1_on_3","bookId":"on","number":3,"niuRound":1,"affectedContent":[{"type":"table","id":"mk19_a_on_t12"},{"type":"question","id":"mk19_a_on_q039"},{"type":"question","id":"mk19_qq_q174"},{"type":"boardbasics","id":"mk19_bb_on_s11"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"8a168b","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Society of Clinical Oncology issued updated guidelines on initial hormonal management of castrate-sensitive advanced, recurrent, or metastatic prostate cancer."]}," Topics discussed include standard initial treatment options for metastatic castrate-sensitive prostate cancer and the use of combination therapies compared with castration monotherapy for patients with castrate-sensitive locally advanced nonmetastatic prostate cancer. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Virgo KS, Rumble RB, de Wit R, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2021;39:1274-1305. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33497248","target":"_blank"},"children":["PMID: 33497248"]}," doi: 10.1200/JCO.20.03256."]}]},{"id":"mk19_niu_1_on_4","bookId":"on","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_a_on_s13_2_1_5"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"a42cb3","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["Guidelines by the International Late Effects of Childhood Cancer Guideline Harmonization Group were published regarding surveillance of central nervous system neoplasms in child, adolescent, and young adult cancer survivors who were treated with cranial radiotherapy."]}," According to these guidelines, surveillance should consist of history and neurologic examinations every 1 to 5 years that focus on suggestive symptoms. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Bowers DC, Verbruggen LC, Kremer LCM, et al. Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22:e196-e206. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/33845037","target":"_blank"},"children":["PMID: 33845037"]}," doi: 10.1016/S1470-2045(20)30688-4."]}]},{"id":"mk19_niu_1_on_5","bookId":"on","number":5,"niuRound":1,"affectedContent":[{"type":"question","id":"mk19_a_on_q010"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"768451","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. Notably, the 13-valent pneumococcal conjugate vaccine has been removed from the schedule to reflect new guidelines. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175:432-443. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]},{"id":"mk19_niu_1_pm_1","bookId":"pm","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_pm_s1_1_7"},{"type":"section","id":"mk19_b_pm_s2_1_4"},{"type":"question","id":"mk19_b_pm_q085"},{"type":"boardbasics","id":"mk19_bb_pm_s1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"31aa01","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Thoracic Society Assembly on Allergy, Immunology, and Inflammation updated recommendations on the use of fractional exhaled nitric oxide to guide treatment of asthma."]}," The panel made a conditional recommendation for fractional exhaled nitric oxide (FeNO)-based care. In patients with asthma in whom treatment is being considered, they suggest that FeNO is beneficial and should be used in addition to usual care. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Khatri SB, Iaccarino JM, Barochia A, et al; American Thoracic Society Assembly on Allergy, Immunology, and Inflammation. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021;204:e97-e109. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34779751","target":"_blank"},"children":["PMID: 34779751"]}," doi:10.1164/rccm.202109-2093ST"]}]},{"id":"mk19_niu_1_pm_2","bookId":"pm","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_pm_s2_2_9_2_8"},{"type":"question","id":"mk19_b_pm_q088"},{"type":"boardbasics","id":"mk19_bb_pm_s4"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175:432-443. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]},{"id":"mk19_niu_1_pm_3","bookId":"pm","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_pm_s8_3_4"},{"type":"section","id":"mk19_b_pm_s8_3_4_1"},{"type":"section","id":"mk19_b_pm_s8_3_4_4"},{"type":"question","id":"mk19_b_pm_q002"},{"type":"question","id":"mk19_qq_q046"},{"type":"boardbasics","id":"mk19_bb_pm_s17"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"aca20d","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Academy of Sleep Medicine clinical practice guideline on referral of adults with obstructive sleep apnea for surgical consultation."]}," The guideline",{"type":"tag","tagName":"strong","attrs":{},"children":[]}," provides recommendations for when health care providers treating obstructive sleep apnea (OSA) should discuss referral for upper airway or bariatric surgery evaluation with adult patients with OSA. Recommendations are based on BMI and tolerance of positive airway pressure. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Kent D, Stanley J, Aurora RN, et al. Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17:2499-2505. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34351848","target":"_blank"},"children":["PMID: 34351848"]}," doi:10.5664/jcsm.9592"]}]},{"id":"mk19_niu_1_pm_4","bookId":"pm","number":4,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_pm_s12_3_1"},{"type":"section","id":"mk19_b_pm_s12_3_3_1"},{"type":"section","id":"mk19_b_pm_s12_3_3_2"},{"type":"section","id":"mk19_b_pm_s12_3_3_3"},{"type":"table","id":"mk19_b_pm_t50"},{"type":"question","id":"mk19_b_pm_q018"},{"type":"question","id":"mk19_b_pm_q035"},{"type":"question","id":"mk19_b_pm_q055"},{"type":"question","id":"mk19_b_pm_q057"},{"type":"question","id":"mk19_b_pm_q068"},{"type":"question","id":"mk19_b_pm_q096"},{"type":"question","id":"mk19_qq_q074"},{"type":"question","id":"mk19_qq_q248"},{"type":"boardbasics","id":"mk19_bb_pm_s23"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"08d7c7","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Surviving Sepsis Campaign international guidelines for the management of sepsis and septic shock."]}," This document",{"type":"tag","tagName":"strong","attrs":{},"children":[]}," provides guidance for the clinician caring for adult patients with sepsis or septic shock in the hospital setting. ",{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49:e1063-e1143. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34605781","target":"_blank"},"children":["PMID: 34605781"]}," doi:10.1097/CCM.0000000000005337"]}]},{"id":"mk19_niu_1_rm_1","bookId":"rm","number":1,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_rm_s3_4"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"3365ec","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American College of Rheumatology released guidelines on topical and systemic treatment of rheumatoid arthritis."]}," The guidelines address therapy with disease-modifying antirheumatic drugs, glucocorticoid use, and treatment in high-risk groups. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1108-1123. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/34101376","target":"_blank"},"children":["PMID: 34101376"]}," doi: 10.1002/art.41752"]}]},{"id":"mk19_niu_1_rm_2","bookId":"rm","number":2,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_rm_s2_4_1_9"},{"type":"boardbasics","id":"mk19_bb_rm_s3"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"b844c8","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The FDA issued a drug safety communication on Janus kinase inhibitors."]}," Tofacitinib, as well as possibly newer medications (baricitinib and upadacitinib), is associated with an increased risk for heart-related events (e.g., myocardial infarction, stroke, cancer, blood clots, and death). ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. September 16, 2021. Accessed October 6, 2021. Available at: ",{"type":"tag","tagName":"a","attrs":{"href":"https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death","target":"_blank"},"children":["https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"]},"."]}]},{"id":"mk19_niu_1_rm_3","bookId":"rm","number":3,"niuRound":1,"affectedContent":[{"type":"section","id":"mk19_b_rm_s4_6_1"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"3d9097","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The American Academy of Orthopaedic Surgeons issued guidelines on management of knee osteoarthritis. "]}," Knee braces or canes are recommended for patients with osteoarthritis of the knee who have impaired ambulation, joint instability, or pain.",{"type":"tag","tagName":"strong","attrs":{},"children":[]}," ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["American Academy of Orthopaedic Surgeons management of osteoarthritis of the knee (non-arthroplasty) evidence-based clinical practice guideline. August 31, 2021. Accessed April 11, 2022. Available at: ",{"type":"tag","tagName":"a","attrs":{"href":"https://www.aaos.org/oak3cpg","target":"_blank"},"children":["https://www.aaos.org/oak3cpg"]}]}]},{"id":"mk19_niu_1_rm_4","bookId":"rm","number":4,"niuRound":1,"affectedContent":[{"type":"question","id":"mk19_b_rm_q043"}],"description":{"type":"tag","tagName":"div","attrs":{},"children":[" ",{"type":"p","hlId":"dc9aa5","children":[{"type":"tag","tagName":"strong","attrs":{},"children":["The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention issued an updated adult immunization schedule."]}," The 2022 immunization schedule includes changes to the recommendations on hepatitis B, herpes zoster, and pneumococcal vaccinations. ",{"type":"tag","tagName":"i","attrs":{},"children":[{"type":"tag","tagName":"i","attrs":{},"children":["(Updated May 2022)"]}]}]}," "]},"references":[{"type":"tag","tagName":"span","attrs":{},"children":["Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. Ann Intern Med. 2022;175:432-443. ",{"type":"tag","tagName":"a","attrs":{"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828","target":"_blank"},"children":["PMID: 35175828"]}," doi:10.7326/M22-0036"]}]}]}